The Economic Times daily newspaper is available online now.

    Stock market update: Nifty Pharma index advances 0.48%

    Synopsis

    The Nifty Pharma index closed 0.48 per cent up at 12545.75.

    NiftyGetty Images
    India 10-year bond yield rose 0.05 per cent to 6.03 after trading in 6.02-6.04 range.
    NEW DELHI: The Nifty Pharma index closed on a positive note on Friday.

    Shares of Natco Pharma(up 2.76 per cent), Lupin(up 1.59 per cent), Alkem Laboratories(up 1.58 per cent), Torrent Pharmaceuticals(up 1.49 per cent) and Aurobindo Pharma(up 1.27 per cent) ended the day as top gainers in the pack.

    On the other hand, Gland Pharma(down 3.9 per cent), Laurus(down 1.08 per cent), Granules India(down 0.68 per cent), Abbott India(down 0.63 per cent) and Biocon(down 0.28 per cent) finished as the top losers of the day.

    The Nifty Pharma index closed 0.48 per cent up at 12545.75.

    Benchmark NSE Nifty50 index ended down 0.4 points at 17624.05, while the BSE Sensex stood up 22.71 points at 59655.06.

    Among the 50 stocks in the Nifty index, 0 ended in the green, while 0 closed in the red.

    Shares of Vodafone Idea, Zomato Ltd., YES Bank, Reliance Power and Tata Steel were among the most traded shares on the NSE.

    Shares of Lambodhara Text, Wendt India, Nirman Agri Genetics, Lumax Auto Tech and Deep Industries Ltd. hit their fresh 52-week highs in today's trade, while Aavas Financiers, BEML Land Assets, Uravi T and Wedge, GRM Overseas and FSN E-Comm(Nykaa)hit their fresh 52-week lows.
    Experience Your Economic Times Newspaper, The Digital Way!
    • Front Page
    • Pure Politics
    • Economy
    • ET Markets
    • More
      (What's moving Sensex and Nifty Track latest market news, stock tips and expert advice on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds.)

      Download The Economic Times News App to get Daily Market Updates & Live Business News.

      ...more
      The Economic Times

      Stories you might be interested in